On December 14, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, 2023 (Press release, Zymeworks, DEC 14, 2022, View Source [SID1234625284]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The GEA cohort of this Phase 2 clinical trial (NCT03929666) was fully recruited as of March 1, 2022 with clinical trial sites in the United States, Canada, Chile and South Korea. Enrollment into the biliary tract cancer and colorectal cancer cohorts of the trial continues. The Phase 2 data in GEA supports zanidatamab development in the Phase 3 HERIZON-GEA-01 study, evaluating zanidatamab in combination with chemotherapy with or without tislelizumab for the first-line treatment of HER2-positive GEA (NCT05152147).
The poster presentation will be available on Thursday, January 19, 2023 on the conference website as well as the Zymeworks website.
Title: Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA)
Lead Author: Elena Elimova, MD, MSc, Princess Margaret Cancer Center, Toronto, Canada
Abstract: 347
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
About Zanidatamab
Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2 and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks has entered into separate agreements with each of BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercial zanidatamab throughout various counties around world.